Results 61 to 70 of about 760 (154)

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline [PDF]

Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because
Andrew F. Shorr, Noayna Arshad, Wael Azzam, Marya D. Zilberberg   +3 more
core   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Failure of durlobactam to restore the susceptibility to meropenem in carbapenem-resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
Durlobactam, a diazabicyclooctane β-lactamase inhibitor, can protect meropenem from hydrolysis of KPC and OXA-48 carbapenemases. This study aims to characterize the genome of a carbapenem-resistant Klebsiella pneumoniae (CRKP) clinical strain with high MIC (256 mg/L) of meropenem in the presence of durlobactam.The strain was recovered from bile and ...
Hongxia Wen, Yu Feng, Zhiyong Zong
openaire   +2 more sources

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Future Microbiology
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older.
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye   +4 more
openaire   +2 more sources

Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies [PDF]

This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases.
Valentyn Oksenych, Arefeh Shojaeian, Sahar Nikjoo Niaragh, Seyedeh Zahra Banihashemian, Setayesh Fakhariyan, Amirabbas Safaripour, Mohammad Amin Hemmati, Atiye Rabbani, Majid Eslami   +8 more
core   +1 more source

Successful Treatment of OXA-23 <i>Acinetobacter baumannii</i> Pneumonia with Sulbactam-Durlobactam in a Liver Transplant Recipient. [PDF]

Infect Drug Resist
Liver transplant recipients face a higher risk of multidrug-resistant (MDR) infections because of preoperative comorbidities, extensive antibiotic use, immunosuppressive therapy, and prolonged mechanical ventilation. Carbapenem-resistant Acinetobacter baumannii (CRAB) remains one of the most challenging pathogens in this group.
Yin G, Liu Z, Fu Z, Zhong Z, Ye S, Pan H.   +5 more
europepmc   +3 more sources

Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii [PDF]

The multiply antibiotic-resistant lineage 1 of Acinetobacter baumannii global clone 1 (GC1) emerged in the 1970s, and subsequently more extensively resistant sublineages have emerged.
Christopher J. Harmer, Ting L. Luo, Patrick T. McGann, Ruth M. Hall, Francois Lebreton   +4 more
core   +1 more source

Sulbactam-durlobactam susceptibility among cefiderocol heteroresistant Acinetobacter

ABSTRACT The ATTACK clinical trial for treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) isolates determined treatment with sulbactam-durlobactam to be efficacious and safe.
Bikash Bogati, Tugba Ozturk, Sarah W. Satola, David S. Weiss   +3 more
openaire   +1 more source

Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study [PDF]

Infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC) are associated with high mortality rates and limited treatment options.
Hamilton-Seth, Robert, Kufel, Wesley D., Fisher, Mark, Mochon, Brian, Martinez, Octavio, Liesman, Rachael, Narayanan, Navaneeth, Harrington, Amanda T., Kirn, Thomas J., Clark, Andrew E., Huse, Holly, Tibbetts, Robert J., Humphries, Romney M., Marino, Jamie, Nicolau, David P., Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group, Potula, Raghava, Argotsinger, Jill, Pierce, Virginia M., Beck, Eric T., Simner, Patricia J., Vu, Christine, Westblade, Lars F., Hankins, Julia D., Buyukyanbolu, Ecem, Abbo, Lilian M., Asempa, Tomefa E., Hand, Jonathan, Riddell, Scott W., Chamberland, Robin R., Daniels, Anne R., Dumm, Rebekah E., Tekle, Tsigereda, Gialanella, Philip   +33 more
core   +1 more source

Management of extensively drug-resistant Acinetobacter baumannii bacteremia with cefiderocol and sulbactam-durlobactam: a case report

ASM Case Reports
ABSTRACT Background Extensively drug-resistant (XDR) Acinetobacter baumannii presents an urgent threat to public health due to its significant morbidity and mortality, with limited evidence-based treatment options.
E. J. Kim, M. Snyder, K. Macaluso, A. Sonyey, F. Segovia, D. Finkel, D. Cennimo, E. L. Kim   +7 more
openaire   +2 more sources